Literature DB >> 3533779

Immunization against fatal experimental Klebsiella pneumoniae pneumonia.

S J Cryz, E Fürer, R Germanier.   

Abstract

The ability of serospecific anti-capsular polysaccharide (CPS) antibody to prevent fatal Klebsiella pneumoniae pneumonia was evaluated in a rat lung model. Rats were immunized intramuscularly with 100 micrograms of purified serotype 2 CPS and challenged intrabronchially 14 days later with a serotype 2 strain of K. pneumoniae. Vaccination engendered high levels of serum anti-CPS antibody which afforded significant protection (P less than 0.01) against fatal pneumonia. Immunization promoted clearance of the challenge bacteria from the lungs and prevented bacteremia. Histological examination of lung tissue from infected control animals showed pronounced inflammatory cellular infiltrate in the alveolar spaces, intra- and peribronchial inflammation, and tissue necrosis. In contrast, pathological changes noted in lungs from immunized animals were restricted to infrequent intra- and peribronchial involvement.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533779      PMCID: PMC260175          DOI: 10.1128/iai.54.2.403-407.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

Review 1.  Aerobic gram-negative bacillary pneumonias.

Authors:  A K Pierce; J P Sanford
Journal:  Am Rev Respir Dis       Date:  1974-11

2.  Resistance to Klebsiella pneumoniae and the importance of two bacterial antigens.

Authors:  J M Cooper; D Rowley
Journal:  Aust J Exp Biol Med Sci       Date:  1982-12

3.  Nosocomial pneumonia. A continuing major problem.

Authors:  J R Graybill; L W Marshall; P Charache; C K Wallace; V B Melvin
Journal:  Am Rev Respir Dis       Date:  1973-11

4.  Antibiotics and travellers' diarrhoea.

Authors:  A M Geddes
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

5.  Lobar pneumonia in rats produced by clinical isolates of Klebsiella pneumoniae.

Authors:  P Domenico; W G Johanson; D C Straus
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

6.  Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

Review 7.  Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients.

Authors:  B E Kreger; D E Craven; P C Carling; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

8.  Experimental Klebsiella pneumoniae burn wound sepsis: role of capsular polysaccharide.

Authors:  S J Cryz; F Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

9.  Local immunity to klebsiella pneumoniae in the lungs of mice.

Authors:  J M Cooper; J J Finlay-Jones; N L Hill; D Rowley
Journal:  J Infect Dis       Date:  1983-02       Impact factor: 5.226

10.  Direct evidence for the involvement of capsular polysaccharide in the immunoprotective activity of Klebsiella pneumoniae ribosomal preparations.

Authors:  M M Riottot; J M Fournier; H Jouin
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

View more
  15 in total

Review 1.  Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae.

Authors:  H Sahly; R Podschun
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Monoclonal antibody against Klebsiella capsular polysaccharide reduces severity and hematogenic spread of experimental Klebsiella pneumoniae pneumonia.

Authors:  T K Held; M Trautmann; M E Mielke; H Neudeck; S J Cryz; A S Cross
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

3.  Comparison of the host responses to wild-type and cpsB mutant Klebsiella pneumoniae infections.

Authors:  Matthew S Lawlor; Scott A Handley; Virginia L Miller
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

4.  Molecular analysis of the contribution of the capsular polysaccharide and the lipopolysaccharide O side chain to the virulence of Klebsiella pneumoniae in a murine model of pneumonia.

Authors:  Guadalupe Cortés; Nuria Borrell; Beatriz de Astorza; Cristina Gómez; Jaume Sauleda; Sebastián Albertí
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

5.  Role of lung epithelial cells in defense against Klebsiella pneumoniae pneumonia.

Authors:  Guadalupe Cortés; Dolores Alvarez; Carles Saus; Sebastián Albertí
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Surface exposure of O1 serotype lipopolysaccharide in Klebsiella pneumoniae strains expressing different K antigens.

Authors:  J M Tomás; S Camprubi; S Merino; M R Davey; P Williams
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

7.  Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans.

Authors:  M Granström; B Wretlind; B Markman; S Cryz
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

8.  Genetic requirements for Klebsiella pneumoniae-induced liver abscess in an oral infection model.

Authors:  Ya-Chun Tu; Min-Chi Lu; Ming-Ko Chiang; Shu-Ping Huang; Hwei-Ling Peng; Hwan-You Chang; Ming-Shiou Jan; Yi-Chyi Lai
Journal:  Infect Immun       Date:  2009-05-11       Impact factor: 3.441

9.  Humoral immunity against capsule polysaccharide protects the host from magA+ Klebsiella pneumoniae-induced lethal disease by evading Toll-like receptor 4 signaling.

Authors:  Ming-Fang Wu; Chih-Ya Yang; Tzu-Lung Lin; Jin-Town Wang; Feng-Ling Yang; Shih-Hsiung Wu; Bor-Shen Hu; Teh-Ying Chou; Ming-Daw Tsai; Chi-Hung Lin; Shie-Liang Hsieh
Journal:  Infect Immun       Date:  2008-11-17       Impact factor: 3.441

10.  Immune enhancement of pulmonary clearance of nontypable Haemophilus influenzae.

Authors:  E J Hansen; D A Hart; J L McGehee; G B Toews
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.